Cord-derived regenerative therapy is redefining how we care for equine joints and soft tissue injuries. Unlike traditional autologous treatments like PRP or BMAC that rely on drawing blood or bone marrow from the horse, cord-derived products use Wharton’s Jelly — a rich source of extracellular matrix (ECM), growth factors, and cytokines. These biologically active components help cushion the joint, reduce inflammation, and promote tissue remodeling at a cellular level.
Ease Of Use and Prep
What sets cord-derived therapy apart is its consistency and ease of use. Products like StrideGuard are processed in a controlled environment, resulting in a ready-to-inject matrix with over 90% ECM retention. This means practitioners can deliver a potent, regenerative solution without delays or prep — no spinning, no blood draw, and no patient-to-patient variability. The result? A faster, more predictable outcome for performance and working horses alike.